Idorsia Ltd announces the end results of the repurchase offer for its outstanding CHF 204 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028. Bondholders have accepted the offer for the CB 2025 with 91.90% of the total issued nominal value and for the CB 2028 with 94.53% of the total issued nominal value. Settlement is expected on August 26, 2025. More information can be found on the company’s website. Idorsia aims to challenge medical paradigms and evolve into a leading biopharmaceutical company based in Switzerland.

Read more at GlobeNewswire: Idorsia publishes end results of repurchase offer for its